After receiving permission for the emergency use of baricitinib in combination with remdesivir for the treatment of suspected cases of covid-19, now Eli Lilly and Company India has bagged a much bigger deal.
Eli Lilly India on Tuesday stated that it has received green signal for emergency use of its antibody drugs combination used for the treatment of mild to moderate Covid-19, in the nation.
The company has received permission for restricted emergency use of its monolconal antibody drugs, bamlanivimab 700 mg and etesevimab 1400 mg, used in combination in the US and specific EU countries for the treatment of the infection”, the company said in a statement.
“Lilly is engaging in active dialogue with the Indian government and regulatory authorities to donate bamlanivimab and etesevimab in order to speed up access and provide treatment options for patients with Covid-19,” it added.
Eli Lilly and Company India, MD, Luca Visini affirmed that they are delighted to have an innovative treatment choice to provide the lucrative offer to India’s healthcare providers across the states, who are constantly grappling against Covid-19.
The much anticipated teaser of Pawan Kalyan’s Hari Hara Veera Mallu has been unveiled and…
Monopoly, the classic board game of buying, selling, and trading properties, has brought families and…
Markset Networks is gearing up to release the comedy horror flick ‘Oo Manchi Ghost’ (OMG),…
Disney+ Hotstar, India’s premier streaming service, is set to premiere the year’s cinematic sensation, ‘Manjummel…
The much anticipated first audio single from Pushpa 2 album has been unveiled by the…
Prabhas is currently the busiest actor in India with five projects lined up. He's juggling…